Senores Pharmaceutic

May 14 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• MARCH-QUARTER CONSOL NET PROFIT 316.1 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.75 BILLION RUPEES

Source text: [ID:]

Further company coverage: SENO.NS

(([email protected];))

April 3 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• ANNOUNCES STRATEGIC JOINT VENTURE IN UNITED STATES

Source text: ID:nNSE802swn

Further company coverage: SENO.NS

(([email protected];;))

** Shares of India's Senores Pharmaceuticals SENO.NS rise about 6% to 828.01 rupees

** Drugmaker posted about 84% rise in quarterly profit y/y on Tuesday

** Co's management maintains revenue and PAT guidance of 50% and 100%, respectively, for FY26

** Trading vols at 969,772 shares, almost 3x the 30-day avg of 348,812 shares

** SENO had risen about 45% in 2025, ~4.5% down so far in 2026

($1 = 91.6910 Indian rupees)

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

Jan 20 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• SENORES PHARMACEUTICALS DEC-QUARTER CONSOL NET PROFIT 316.6 MILLION RUPEES

• SENORES PHARMACEUTICALS DEC-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 1.75 BILLION RUPEES

Source text: ID:nnAZN4S18R5

Further company coverage: SENO.NS

(([email protected];))

Jan 7 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• BOARD APPROVES ISSUANCE OF WARRANTS UPTO 950 MILLION RUPEES

• ISSUE PRICE SET AT 812 RUPEES PER WARRANT

Source text: ID:nBSE5fq0zb

Further company coverage: SENO.NS

(([email protected];))

Sept 18 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• SENORES PHARMACEUTICALS - INVESTMENT OF $2 MILLION THROUGH RIGHTS ISSUE IN US UNIT

Source text: ID:nBSEfyK55

Further company coverage: SENO.NS

(([email protected];))

July 28 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• SENORES PHARMACEUTICALS LTD - HAVIX COMPLETES USFDA INSPECTION WITH 3 OBSERVATIONS

• SENORES PHARMACEUTICALS LTD - HAVIX TO RESPOND TO MINOR OBSERVATIONS WITHIN 15 DAYS

Source text: ID:nBSE62ZHyy

Further company coverage: SENO.NS

(([email protected];))

** Shares of Senores Pharma SENO.NS jump record high 13% to 698 rupees

** Drugmake posts a 94% Y/Y rise in June-qtr net profit; rev from ops rises 71.6% Y/Y

** More than 3.5 mln shares change hands, 12.8x of 30-day avg

** Stock up 21% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

May 5 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• SENORES PHARMACEUTICALS LTD - ACQUIRES USFDA-APPROVED ANDA FOR TOPIRAMATE TABLETS

• SENORES PHARMACEUTICALS LTD - ACQUISITION FUNDED THROUGH IPO PROCEEDS

Source text: ID:nBSE3m6TdK

Further company coverage: SENO.NS

(([email protected];;))

** Carraro India CARD.NS slides 8.5%; Ventive Hospitality VENE.NS drops ~5%

** Senores Pharma SENO.NS down 3% and Tolins Tyres TOLI.NS flat

** 3-months lock-in expires for VENE (2% shares), CARD (5%) and SENO (7%); and 6-month lock-in expires for TOLI (54%), per Nuvama

** Since Dec 30 listings, VENE up 10% and SENO surges ~47%, while CARD tumbled 55%

** TOLI slides 49% since Sept 16 listing

** 72 lock-ins expire from March 17 to May 30 but not all shares will be for sale given promoters' sizeable stakes -Nuvama

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

March 20 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• INVESTMENT OF $468,640 IN SPI THROUGH RIGHTS ISSUE

Source text: ID:nNSE9RpTpL

Further company coverage: SENO.NS

(([email protected];;))

March 4 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• ACQUIRES 14 ANDAS FROM DR. REDDY'S LABORATORIES

• ACQUISITION INCLUDES 13 APPROVED ANDAS AND 1 PENDING APPROVAL

• ADDRESSABLE OPPORTUNITY OF ACQUIRED ANDAS IN USA APPROX. $421 MILLION

Source text: ID:nBSEcxCc7

Further company coverage: SENO.NS

(([email protected];;))

Feb 26 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• SENORES PHARMACEUTICALS - COMMENCED MANUFACTURING AT SECOND API MANUFACTURING FACILITY IN GUJARAT

Source text: ID:nBSE1JM3dp

Further company coverage: SENO.NS

(([email protected];;))

** Shares of Senores Pharmaceuticals Ltd SENO.NS rise as much as 5.8% to 565 rupees

** Co via its unit acquires USFDA-approved abbreviated new drug application (ANDA) for Roflumilast 250 mcg, 500 mcg tablets used to treat flare-ups in people with severe chronic obstructive pulmonary disease

** Adds, acquisition will be funded through initial public offer proceeds

** Stock on track to gain for 3rd straight day

** SENO last up 4%, cutting YTD losses to 6.1%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

** Shares of Senores Pharmaceuticals SENO.NS rise as much as 17.2% to 584.05 rupees

** SENO reports Q3 consol net profit more than doubled Y/Y to 171.8 mln rupees ($2.1 mln), rev from ops rose 31% Y/Y to 1.03 bln rupees

** More than 3.6 mln shares change hands, 2.2x of 30-day avg since listing on Dec. 30

** Since listing stock is down 10.3%

($1 = 86.4825 Indian rupees)

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Jan 20 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• SENORES PHARMACEUTICALS - MADE A FURTHER INVESTMENT IN SENORES PHARMACEUTICALS INC.

• SENORES PHARMACEUTICALS LTD - INVESTMENT OF USD 1.3 MILLION

Source text: ID:nBSE6kV0ZF

Further company coverage: SENO.NS

(([email protected];))

** Senores Pharmaceuticals SENO.NS soars as much as ~56% to 609.65 rupees in debut trade; last up 41.7%

** Stock opened at 600 rupees, ~54% higher than its IPO price of 391 rupees

** Senores' IPO consisted of 5 bln rupees (~$59 mln) worth of fresh issue of shares and 2.1 mln shares as offer for sale

** IPO subscribed 93.69 times, garnering bids worth 312.64 bln rupees - exchange data

** Co says proceeds will be used to invest in units to set up manufacturing facility, debt repayment and general corporate purposes

($1 = 85.4590 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))